Ligand to acquire Apeiron Biologics for US$100 million
Acquisition provides Ligand with the royalty rights to QARZIBA, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A.
Acquisition provides Ligand with the royalty rights to QARZIBA, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A.
Vabysmo PFS is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that can cause blindness
Dr. Sanjay Behari, Director of Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, as the President of the Medical Assessment and Rating Board
Yann d’Hervé takes over responsibility for the Health Care business at Evonik, effective July 1
The integration of SAP S/4HANA Cloud will equip Cupid Limited with a comprehensive suite of integrated applications,
Ibara will drive AI-powered clinical research innovation
Imfinzi also recommended for patients with mismatch repair deficient disease
Doxycycline capsules are indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients
Doses will be ready to ship to applicable EU member states immediately upon authorization by the European Commission
Subscribe To Our Newsletter & Stay Updated